Close monitoring and lifetime follow-up is optimal for patients with a history of melanoma.
Malignant melanoma, a potentially lethal form of skin cancer, is becoming more common each year in the United States and worldwide. The cure rate, however, is also increasing due to better education, earlier detection, and more effective treatment. Thus, there are more melanoma survivors who are at risk for recurrence of melanoma and also a second primary. Because there are few prospective screening and surveillance results in the medical literature, recommendations for follow-up of melanoma survivors have been based on the natural history of the disease, physical examinations, laboratory tests, and radiologic evaluations.
Christianson
David F
DF
Department of Internal Medicine, University of Missouri Health Care, Ellis Fischel Cancer Center, Columbia, MO 65203, USA.
Anderson
Clay M
CM
D019411:Clinical Laboratory Techniques; D003266:Continuity of Patient Care / Q000592:standards*; D003952:Diagnostic Imaging; D018450:Disease Progression; D006801:Humans; D008403:Mass Screening / Q000592:standards*; D008545:Melanoma / Q000175:diagnosis* / Q000517:prevention & control / Q000556:secondary*; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000517:prevention & control; D016609:Neoplasms, Second Primary / Q000175:diagnosis* / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D011379:Prognosis; D012306:Risk